CT071 car-t cells for relapsed multiple myeloma or plasma cell leukemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new car-t cell therapy called CT071 that targets a protein called GPRC5D on myeloma cells. It is for patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have relapsed or refractory multiple myeloma or plasma cell leukemia.
- You must have tried at least one previous treatment (for plasma cell leukemia) or a specific set of treatments (for multiple myeloma) and your cancer must have stopped responding to the last treatment.
- You must be able to have cells collected through a process called apheresis.
- You must be in fairly good health, with a performance status of 0 or 1 on the ECOG scale.
- You cannot be pregnant or breastfeeding, and you must use effective birth control for at least 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins on myeloma cells (BCMA and GPRC5D). It is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments.
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.